Seiichi Fuziwara-Ruíz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Seiichi Fuziwara-Ruíz has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Andrés Martínez-Cornelio
Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Oncología, Servicio de Urología. Ciudad de México, México
1 shared publication - Arturo Delgado-Herrera
Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Oncología, Servicio de Urología. Ciudad de México, México
1 shared publication - Cristobal Castro-Chávez
Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Oncología, Servicio de Urología. Ciudad de México, México
1 shared publication - Devang Desai
Department of Urology Toowoomba Hospital Toowoomba Australia
1 shared publication - Joel Quintero-Becerra
Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Ciudad de México, México
1 shared publication - Juan Carlos Huerta-Gómez
Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Oncología, Servicio de Urología. Ciudad de México, México
1 shared publication
Latest Publications
- Open Access
- 6 May 2026
- Vol. 64 (3) , e6880
[First cohort: Robotic radical prostatectomy at the Mexican Institute for Social Security].
Prostate cancer is the most common cancer in men and the leading cause of malignancy-related mortality in Mexico. The Mexican Institute for Social Security (IMSS for its initialism in Spanish) introduced its first robotic system at the Oncology Hospital of the 21st Century National Medical Center in Mexico City. To evaluate the accumulated experience, perioperative, oncologic and functional outcomes of the first 200 robot-assisted radical prostatectomy (RARP) cases. A retrospective analysis of 200 patients undergoing RARP for localized prostate cancer was conducted. Perioperative and postoperative variables, pathology results, complications, and one-year continence rates were considered. Mean surgical time was 242.1 minutes (90-600), with a console time of 197.6 minutes (68-495). Mean blood loss was 327.7 cc (10-1800). Positive surgical margins were observed in 34.5% of cases. Complications occurred in 22 patients (11%). No conversions to open surgery or mortality were reported. Mean hospital stay was 2.54 days (2-14). Postoperative antigen was undetectable in 88.5% of patients. The continence rate was 95.7%. The first 200 RARP cases at our institution demonstrate the accumulated experience with the procedure, showing low complication rates. These results are consistent with those of high-volume centers, which require additional long-term functional follow-up.
- 6 May 2026
- Vol. 64 (3) , e6880
Open Access[First cohort: Robotic radical prostatectomy at the Mexican Institute for Social Security].
Prostate cancer is the most common cancer in men and the leading cause of malignancy-related mortality in Mexico. The Mexican Institute for Social Security (IMSS for its initialism in Spanish) introduced its first robotic system at the Oncology Hospital of the 21st Century National Medical Center in Mexico City. To evaluate the accumulated experience, perioperative, oncologic and functional outcomes of the first 200 robot-assisted radical prostatectomy (RARP) cases. A retrospective analysis of 200 patients undergoing RARP for localized prostate cancer was conducted. Perioperative and postoperative variables, pathology results, complications, and one-year continence rates were considered. Mean surgical time was 242.1 minutes (90-600), with a console time of 197.6 minutes (68-495). Mean blood loss was 327.7 cc (10-1800). Positive surgical margins were observed in 34.5% of cases. Complications occurred in 22 patients (11%). No conversions to open surgery or mortality were reported. Mean hospital stay was 2.54 days (2-14). Postoperative antigen was undetectable in 88.5% of patients. The continence rate was 95.7%. The first 200 RARP cases at our institution demonstrate the accumulated experience with the procedure, showing low complication rates. These results are consistent with those of high-volume centers, which require additional long-term functional follow-up.
- 13 July 2021
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 47 (4) , 319-324
Redo pelvic fracture urethral injury repair: The case for tadalafil
Objective: To define the role of tadalafil in improving outcomes of redo urethroplasty for pelvic fracture urethral injury (PFUI). PFUI is common in developing countries, invariably as a result of road traffic trauma. Repair is complex, and redo cases are even more challenging. Material and methods: This was a longitudinal prospective nonrandomized study between 2017 and 2019. Men undergoing redo-urethroplasty were nonrandomized into two groups. Group 1 received tadalafil 5 mg the next day after surgery and continued for 3 months, and group 2 did not receive tadalafil. Inclusion criteria were patients undergoing redo-urethroplasty willing to trial low-dose tadalafil post-operatively. Exclusion criteria were 1 endoscopic intervention. Primary success was 83.3%. Success with tadalafil was 96.6%, compared to 71.0% in the non-Tadalafil group (P ¼ .0008). Only one patient on tadalafil failed, compared with nine in the non-tadalafil group. Secondary success rate was defined as the need for a single subsequent endoscopic intervention and was 93.3%. Conclusion: In our series, there was improved outcome with using tadalafil in patients having redo urethroplasty for PFUI. Further trials should be done to evaluate the use in all PFUI cases. Cite this article as: Joshi PM, Desai D, Fuziwara S, Raveenthiran S, Nafea M, Kulkarni SB. Redo pelvic fracture urethral injury repair: The case for tadalafil. Turk J Urol. 2021;47(4):319-324.
- 13 July 2021
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 47 (4) , 319-324
Redo pelvic fracture urethral injury repair: The case for tadalafil
Objective: To define the role of tadalafil in improving outcomes of redo urethroplasty for pelvic fracture urethral injury (PFUI). PFUI is common in developing countries, invariably as a result of road traffic trauma. Repair is complex, and redo cases are even more challenging. Material and methods: This was a longitudinal prospective nonrandomized study between 2017 and 2019. Men undergoing redo-urethroplasty were nonrandomized into two groups. Group 1 received tadalafil 5 mg the next day after surgery and continued for 3 months, and group 2 did not receive tadalafil. Inclusion criteria were patients undergoing redo-urethroplasty willing to trial low-dose tadalafil post-operatively. Exclusion criteria were 1 endoscopic intervention. Primary success was 83.3%. Success with tadalafil was 96.6%, compared to 71.0% in the non-Tadalafil group (P ¼ .0008). Only one patient on tadalafil failed, compared with nine in the non-tadalafil group. Secondary success rate was defined as the need for a single subsequent endoscopic intervention and was 93.3%. Conclusion: In our series, there was improved outcome with using tadalafil in patients having redo urethroplasty for PFUI. Further trials should be done to evaluate the use in all PFUI cases. Cite this article as: Joshi PM, Desai D, Fuziwara S, Raveenthiran S, Nafea M, Kulkarni SB. Redo pelvic fracture urethral injury repair: The case for tadalafil. Turk J Urol. 2021;47(4):319-324.